Spedox-6

PreclinicalSmall molecule

UUniversity of California, Irvine

Spedox-6 is one of 55 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaRecruiting

Soft Tissue SarcomaPreclinical

Recruiting

Competition

Competitive Landscape

60 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Votrient

Novartis

Approved

14 2

Adriamycin

Pfizer

Phase 3

36 3

Adriamycin

Pfizer

Phase 3

27 4

Lynparza

AstraZeneca

Approved

1 5

Idamycin

Pfizer

Approved

—6

Ifex

BBaxter Healthcare Corporation

Phase 3

32 7

Yondelis

AApotex Inc.

Phase 3

16 8

Treanda

AAzurity Pharmaceuticals

Farydak

Neulasta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalRecruiting

Soft Tissue Sarcoma

NCT07064018

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Recruiting·UUniversity of California, Irvine·Preclinical·NCT07064018·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spedox-6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spedox-6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spedox-6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Irvine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, Irvine

Spedox-6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News